Eintrag weiter verarbeiten
Prognostic Factors in Follicular Lymphoma
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Journal of Clinical Oncology, 28, 2010, 17, S. 2902-2913 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Relander, Thomas Johnson, Nathalie A. Farinha, Pedro Connors, Joseph M. Sehn, Laurie H. Gascoyne, Randy D. Relander, Thomas Johnson, Nathalie A. Farinha, Pedro Connors, Joseph M. Sehn, Laurie H. Gascoyne, Randy D. |
|---|---|
| author |
Relander, Thomas Johnson, Nathalie A. Farinha, Pedro Connors, Joseph M. Sehn, Laurie H. Gascoyne, Randy D. |
| spellingShingle |
Relander, Thomas Johnson, Nathalie A. Farinha, Pedro Connors, Joseph M. Sehn, Laurie H. Gascoyne, Randy D. Journal of Clinical Oncology Prognostic Factors in Follicular Lymphoma Cancer Research Oncology |
| author_sort |
relander, thomas |
| spelling |
Relander, Thomas Johnson, Nathalie A. Farinha, Pedro Connors, Joseph M. Sehn, Laurie H. Gascoyne, Randy D. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2009.26.1693 <jats:p> Follicular lymphoma (FL) is one of the most common types of non-Hodgkin's lymphoma. It is usually diagnosed at an advanced stage, for which many treatment options exist, however, no curative standard therapy has been identified. The outcome is highly variable with a median survival of approximately 10 years. The life expectancy of patients with FL has been extended with the use of rituximab, a monoclonal antibody targeting the CD20 antigen on FL cells, but there remains a group of patients who fail to respond to chemoimmunotherapy and die early of their disease. Transformation of FL to an aggressive histology is an important event with high morbidity and mortality. The Follicular Lymphoma International Prognostic Index has become the clinically useful prognostic tool, but gives only a rough estimate of expected outcome. There is a need for useful biomarkers for prediction of the disease course of single patients to individualize therapy, especially in the new era of chemoimmunotherapy. </jats:p> Prognostic Factors in Follicular Lymphoma Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2009.26.1693 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOS4yNi4xNjkz |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOS4yNi4xNjkz |
| institution |
DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
American Society of Clinical Oncology (ASCO), 2010 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2010 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
relander2010prognosticfactorsinfollicularlymphoma |
| publishDateSort |
2010 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Prognostic Factors in Follicular Lymphoma |
| title_unstemmed |
Prognostic Factors in Follicular Lymphoma |
| title_full |
Prognostic Factors in Follicular Lymphoma |
| title_fullStr |
Prognostic Factors in Follicular Lymphoma |
| title_full_unstemmed |
Prognostic Factors in Follicular Lymphoma |
| title_short |
Prognostic Factors in Follicular Lymphoma |
| title_sort |
prognostic factors in follicular lymphoma |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2009.26.1693 |
| publishDate |
2010 |
| physical |
2902-2913 |
| description |
<jats:p> Follicular lymphoma (FL) is one of the most common types of non-Hodgkin's lymphoma. It is usually diagnosed at an advanced stage, for which many treatment options exist, however, no curative standard therapy has been identified. The outcome is highly variable with a median survival of approximately 10 years. The life expectancy of patients with FL has been extended with the use of rituximab, a monoclonal antibody targeting the CD20 antigen on FL cells, but there remains a group of patients who fail to respond to chemoimmunotherapy and die early of their disease. Transformation of FL to an aggressive histology is an important event with high morbidity and mortality. The Follicular Lymphoma International Prognostic Index has become the clinically useful prognostic tool, but gives only a rough estimate of expected outcome. There is a need for useful biomarkers for prediction of the disease course of single patients to individualize therapy, especially in the new era of chemoimmunotherapy. </jats:p> |
| container_issue |
17 |
| container_start_page |
2902 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
28 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792339926323298307 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:54:56.604Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Prognostic+Factors+in+Follicular+Lymphoma&rft.date=2010-06-10&genre=article&issn=1527-7755&volume=28&issue=17&spage=2902&epage=2913&pages=2902-2913&jtitle=Journal+of+Clinical+Oncology&atitle=Prognostic+Factors+in+Follicular+Lymphoma&aulast=Gascoyne&aufirst=Randy+D.&rft_id=info%3Adoi%2F10.1200%2Fjco.2009.26.1693&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792339926323298307 |
| author | Relander, Thomas, Johnson, Nathalie A., Farinha, Pedro, Connors, Joseph M., Sehn, Laurie H., Gascoyne, Randy D. |
| author_facet | Relander, Thomas, Johnson, Nathalie A., Farinha, Pedro, Connors, Joseph M., Sehn, Laurie H., Gascoyne, Randy D., Relander, Thomas, Johnson, Nathalie A., Farinha, Pedro, Connors, Joseph M., Sehn, Laurie H., Gascoyne, Randy D. |
| author_sort | relander, thomas |
| container_issue | 17 |
| container_start_page | 2902 |
| container_title | Journal of Clinical Oncology |
| container_volume | 28 |
| description | <jats:p> Follicular lymphoma (FL) is one of the most common types of non-Hodgkin's lymphoma. It is usually diagnosed at an advanced stage, for which many treatment options exist, however, no curative standard therapy has been identified. The outcome is highly variable with a median survival of approximately 10 years. The life expectancy of patients with FL has been extended with the use of rituximab, a monoclonal antibody targeting the CD20 antigen on FL cells, but there remains a group of patients who fail to respond to chemoimmunotherapy and die early of their disease. Transformation of FL to an aggressive histology is an important event with high morbidity and mortality. The Follicular Lymphoma International Prognostic Index has become the clinically useful prognostic tool, but gives only a rough estimate of expected outcome. There is a need for useful biomarkers for prediction of the disease course of single patients to individualize therapy, especially in the new era of chemoimmunotherapy. </jats:p> |
| doi_str_mv | 10.1200/jco.2009.26.1693 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOS4yNi4xNjkz |
| imprint | American Society of Clinical Oncology (ASCO), 2010 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2010 |
| institution | DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T15:54:56.604Z |
| match_str | relander2010prognosticfactorsinfollicularlymphoma |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 2902-2913 |
| publishDate | 2010 |
| publishDateSort | 2010 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Relander, Thomas Johnson, Nathalie A. Farinha, Pedro Connors, Joseph M. Sehn, Laurie H. Gascoyne, Randy D. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2009.26.1693 <jats:p> Follicular lymphoma (FL) is one of the most common types of non-Hodgkin's lymphoma. It is usually diagnosed at an advanced stage, for which many treatment options exist, however, no curative standard therapy has been identified. The outcome is highly variable with a median survival of approximately 10 years. The life expectancy of patients with FL has been extended with the use of rituximab, a monoclonal antibody targeting the CD20 antigen on FL cells, but there remains a group of patients who fail to respond to chemoimmunotherapy and die early of their disease. Transformation of FL to an aggressive histology is an important event with high morbidity and mortality. The Follicular Lymphoma International Prognostic Index has become the clinically useful prognostic tool, but gives only a rough estimate of expected outcome. There is a need for useful biomarkers for prediction of the disease course of single patients to individualize therapy, especially in the new era of chemoimmunotherapy. </jats:p> Prognostic Factors in Follicular Lymphoma Journal of Clinical Oncology |
| spellingShingle | Relander, Thomas, Johnson, Nathalie A., Farinha, Pedro, Connors, Joseph M., Sehn, Laurie H., Gascoyne, Randy D., Journal of Clinical Oncology, Prognostic Factors in Follicular Lymphoma, Cancer Research, Oncology |
| title | Prognostic Factors in Follicular Lymphoma |
| title_full | Prognostic Factors in Follicular Lymphoma |
| title_fullStr | Prognostic Factors in Follicular Lymphoma |
| title_full_unstemmed | Prognostic Factors in Follicular Lymphoma |
| title_short | Prognostic Factors in Follicular Lymphoma |
| title_sort | prognostic factors in follicular lymphoma |
| title_unstemmed | Prognostic Factors in Follicular Lymphoma |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2009.26.1693 |